Jaguar Animal Health (JAGX) has provided an announcement.
Jaguar Health, Inc. recently unveiled promising Phase 3 trial outcomes for crofelemer, their innovative drug designed to assist cancer patients with supportive care. While the release of this information has sparked interest, the company has clarified that it is not an attempt to sell or solicit securities; rather, it’s purely informational and not legally filed under the Securities Exchange Act of 1934. This news has the potential to excite investors and stakeholders keen on the company’s progress and future prospects in the pharmaceutical market.
For an in-depth examination of JAGX stock, go to TipRanks’ Stock Analysis page.
